International Brand Name:
In treatment of:
Management of cardiac arrhythmias
Nausea ;Vomiting; Diarrhoea; Ringing in ears ; Deafness; Vertigo; Headache; Visual impairment; Mood changes; Delirium; Arrhythmias; Prolongs QRS complex and Q-T intervals; Ventricular failure and Cardiac arrest; Fever; Angioedema; Asthma; Vascular collapse; Thrombocytopenia(rare); Fall in BP; Syncope; Paradoxical ventricular tachycardia; AV block; SA block; Abdominal pain; Allergic manifestations; Respiratory arrest; Hepatotoxicity
Hypersensitivity to the drug ; Heart block; Long Q-T interval; Congestive heart failure; Hypotensive state; History of embolism; Myasthenia gravis; Digitalis intoxication
Renal impairment ; Hepatic impairment ;Asthma Muscle weakness; Infection accompanied by fever because hypersensitivity reactions are masked.
Amiodarone: Increase in quinidine-serum levels which may result in fatal cardiac dysarrhythmias. Antacids: Increase in quinidine-serum levels resulting in toxicity.Barbiturates: Decreased serum levels of quinidine.Cholinergic drugs: May result in failure to terminate paroxysmal supraventricular tachycardia.Hydantoins: Decrease in efficacy of quinidine may occur.Nifedipine: Decrease in serum levels of quinidine. Urinary alkalinizers: Increase in efficacy of quinidine. Verapamil: Hypotension, bradycardia, ventricular tachycardia, AV block & pulmonary oedema. Anticholinergics: Additive vagolytic effect. Anticoagulants: Activity of anticoagulants potentiated, bleeding may occur. Beta-blockers: Effects of metoprolol or propanolol may be increased. Cardiac glycosides: Increased pharmacologic effects and toxicity of cardiac glycosides. Disopyramide: Increased disopyramide levels or decreased quinidine levels may occur. Non-depolarising muscle blockers: Efficacy enhanced by quinidine. Procainamide: Increased effects of procainamide with resultant toxicity may occur. Propafenone: Efficacy of propafenone enhanced. Succinylcholine: Neuromuscular blockade of succinylcholine may be prolonged. TCAs: Increased pharmacologic effects of TCAs.
First give test dose of 50 to 200mg. Then give 200 to 400mg three times daily or four times daily. Further increase in dose if required until therapeutic response is obtained or toxic effect is started.Maximum dose: 3 to 4gm/day.Children: First give test dose of 2mg/kg. Then give 30mg/kg/day in four to six divided doses.